B-MS opens down as profits miss estimates

26 October 2017
bristol_myers_squibb_big

Bristol-Myers Squibb (NYSE: BMY) has posted profits from the latest quarter that missed analysts’ expectations.

The US pharma major did beat Wall Street estimates with its revenue from the third quarter, of $5.25 billion, which was a 7% rise on the same three months of 2016 and above the $5.19 billion that analysts expected.

Earnings for the latest quarter declined to $845 million, or $0.51 per share, from $1.2 billion, or $0.72 per share in the year-earlier period. Adjusted earnings-per-share were $0.75, below the Wall Street estimate of $0.77.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical